DSS Inc (DSS) Stock Analysis
Verdict: AVOID
Severe cash burn and negative equity threaten imminent shareholder dilution despite short-term subsidiary spin-off momentum.
Investment score: 21/100
Analysis as of
Is DSS Inc stock worth reviewing? The TradeMates thesis
The TradeMates model recommends AVOIDING DSS Inc due to imminent liquidity risk, severe operating losses (-$14.4M USD operating income in 2025), negative equity, and persistent dilution.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
DSS Inc opportunities and risks
What speaks for DSS
- Impact Biomedical business combination catalyst
What speaks against DSS
- Imminent cash runway exhaustion and severe dilution risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| DSS | n/a | 0.4x | n/a | -20.8% | -149.8% | -164.3% |
| BRC | 19.7x | 2.4x | 12.4x | 51.7% | 12.4% | 4.8% |
| DLX | 10.6x | 0.5x | 6.4x | 52.5% | 4.8% | 21.5% |
| EBF | 12.7x | 1.4x | 7.0x | 30.8% | 10.8% | 10.2% |
| QUAD | 15.1x | 0.2x | 6.1x | 32.1% | 1.1% | 10.0% |
| LMTI | n/a | 0.3x | n/a | 22.6% | -4.6% | 4.4% |
| Peer median | 12.7x | 0.5x | 6.4x | 32.1% | 4.8% | 10.0% |
Frequently asked questions about DSS Inc (DSS)
Is DSS stock a good investment?
The TradeMates model rates DSS Inc as AVOID with an investment score of 21/100. The TradeMates model recommends AVOIDING DSS Inc due to imminent liquidity risk, severe operating losses (-$14.4M USD operating income in 2025), negative equity, and persistent dilution. This is algorithmic model output, not personal investment advice.
Is DSS stock a buy?
The TradeMates model verdict for DSS is AVOID with an investment score of 21/100. Treat this as a model signal to review, not a personal buy recommendation.